Rajiv Agarwal

72PUBLICATIONS
137CO-AUTHORS
Molecular targetsCardiology (incl. cardiovascular diseases)Epigenetics (incl. genome methylation and epigenomics)Neurology and neuromuscular diseasesEpidemiological modelling
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (72)

|Aug 08, 2026
Individualizing pharmacologic and non-pharmacologic therapy for CKD associated with diabetes.

|Jun 26, 2026
Systolic blood pressure and albuminuria reduction mediate cardiovascular benefits of finerenone in T2 diabetes and CKD.

|Jun 15, 2026
Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Albuminuria Irrespective of Baseline HbA1c Levels: A Participant-Level Exploratory Analysis of the Randomised CONFIDENCE Trial.

|Jun 05, 2026
Finerenone in Persons with Chronic Kidney Disease without Diabetes.

|Jun 05, 2026
Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure.

|Apr 07, 2026
Authors' Reply: Addressing Disparity Efficacy of Finerenone-Empagliflozin Combination in Asian Patients with Diabetic Kidney Disease.

Rajiv Agarwal

Pageof 12

Frequent Collaborators

19 joint publications

Peter Rossing

17 joint publications

Hiddo J L Heerspink

13 joint publications

Muthiah Vaduganathan

11 joint publications

George L Bakris